Genomma Lab Internacional stock (MXP4693Q1093): Recent trading update

Genomma Lab Internacional, a leading player in consumer healthcare products, saw its shares close at 16.81 MXN on the BMV as of the latest session, down 0.04 MXN or 0.24%, Investing.com as of 05/13/2026. This modest movement comes amid ongoing market activity for Mexican equities. The company, listed under LABB, maintains a presence in the pharmaceuticals and biotech sector with products targeting everyday health needs.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Genomma Lab Internacional: core business model

Genomma Lab Internacional develops, manufactures, and markets over-the-counter (OTC) medicines and personal care products primarily in Mexico and other Latin American countries. The company's portfolio includes well-known brands like Asepxia for acne treatment, Boiron homeopathic remedies, and PropoliD for oral health. This direct-to-consumer model leverages mass-market advertising and distribution through pharmacies and retail chains. For US investors, exposure comes via the Mexican market's ties to North American trade dynamics under USMCA.

Main revenue and product drivers for Genomma Lab Internacional

Key revenue stems from branded generics and consumer health products, with dermatology, pain relief, and digestive health categories leading sales. The firm reported trailing twelve-month revenue of approximately Mex$9.75 billion equivalent in recent analyses, alongside earnings of Mex$2.33 billion TTM, per Simply Wall St data as of 05/2026. Growth drivers include expanding e-commerce and international exports, particularly to the US border regions where Mexican pharma brands gain traction among bilingual consumers.

Conclusion

Genomma Lab Internacional continues to serve the growing Latin American consumer health market with its established brands and distribution network. Recent trading shows stability on the BMV, with shares around 16.81 MXN. US investors may note its relevance through regional trade links, though currency and regulatory factors apply. Market conditions remain key to watch.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.